Skip to content

Personalized Transcranial Direct Current Stimulation in Stroke Recovery

Personalized Transcranial Direct Current Stimulation in Stroke Recovery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06286800
Enrollment
80
Registered
2024-02-29
Start date
2024-12-18
Completion date
2027-09-14
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Stroke, Hemorrhage Brain, Ischemic Stroke, Stroke

Keywords

tdcs, noninvasive cortical stimulation, functional connectivity, hemiparesis, arm weakness

Brief summary

The central objective of this application is to explore the neural substrate of personalized tDCS (ptDCS) and to determine whether the paradigm for each stroke patient can predict the amount of sustained clinical improvement through increased connectivity as measured by a biomarker of plasticity.

Detailed description

This is a randomized, sham controlled double masked parallel group study with optional crossover of chronic (\>3mo from stroke onset) ischemic or hemorrhagic stroke patients to test the effect of ptDCS on a cerebral connectivity biomarker of plasticity during stimulation and after 10 treatment of up to 2 mA ptDCS. PtDCS will be performed during the first 20 minutes of occupational therapy targeting the weaker arm compared to sham. Patients will have the option to cross over after the completion of 1-month follow-up and will complete the same procedures with real tDCS if they were in the sham group.

Interventions

DEVICETranscranial direct current stimulation (tDCS) with OT

Weak direct current (0.5-2 mA) will be delivered for up to 20 minutes through surface electrodes which will be positioned using the ptDCS montage. The current will be increased and decreased ramp-like at the beginning and end of the 20-minute stimulation to lessen the itchy/numb skin sensation and decrease the likelihood of an innocuous phosphene-like visual phenomenon. The stimulation will be delivered during the first 20 minutes of occupational therapy targeted to the more affected upper extremity.

DEVICESham tDCS with OT

Same procedure and montage as with the active stimulation but the current will be increased then decreased ramp-like and switched off after 20 seconds instead of the 20 minutes to elicit the same cutaneous sensation as the other stimulation conditions. \[69\] This short length of stimulation is documented to elicit sensations comparable to those of real stimulation. With this procedure, subjects were unable to differentiate between tDCS and sham stimulation in our and other previous studies.

Sponsors

The Methodist Hospital Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Symptomatic ischemic or hemorrhagic stroke verified by computerized axial tomography or magnetic resonance imaging resulting in hemiparesis (MRC 1-4). * Age more than 18, Male or Female, All racial and ethnic groups * Entry into the study \>3 months post onset * Modified Ashworth Scale Score \<3 in the involved upper extremity * Passive range of motion within functional ranges at the shoulder, elbow, wrist and hand * Able to follow 2 step commands

Exclusion criteria

* Patients with history of severe alcohol or drug abuse, psychiatric illnesses like severe depression, poor motivational capacity, or severe language disturbances, particularly of receptive nature or with serious cognitive deficits (defined as unable to follow study instructions). * Patients with bilateral paresis, or weakness or sensory damage due to peripheral causes (e.g. peripheral nerve injury, muscle or orthopedic injury etc.) * Patients with severe uncontrolled medical problems (e.g. cardiovascular disease, severe rheumatoid arthritis, active joint deformity of arthritic origin, active cancer or renal disease, any kind of end-stage pulmonary or cardiovascular disease, or a deteriorated condition due to age,epilepsy or others). * Patients with unstable cardiac arrhythmia. * Pregnancy * Patients with metallic implants in the head, patients with pacemakers, patients with craniotomies, including burr holes who cannot be safely stimulated * Patients with seizures * Non-English speaking individuals will only be eligible if they can provide the appropriate translator for all the sessions of the study as no funding is available to pay for such services.

Design outcomes

Primary

MeasureTime frameDescription
fMRI functional connectivity biomarkerbaseline and 4 weeksTask activation, resting state functional connectivity

Secondary

MeasureTime frameDescription
Wolf Motor Function Test4 weeksA time-based measurement of upper extremity function of 17 tasks. Shorter performance time is better.
Fugl-Meyer assessment4 weeksThe upper extremity component of Fugl-Meyer test (uFM) is a widely used cumulative numeric rating tool that assesses motor impairment. Range is 0-66, higher score is better.

Countries

United States

Contacts

CONTACTNeha Sudarshan, MD
nsudarshan@houstonmethodist.org9082277275
CONTACTTimea Hodics, MD
tmhodics@houstonmethodist.org281-381-1728
PRINCIPAL_INVESTIGATORTimea Hodics, MD

The Methodist Hospital Research Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026